Value-Based Cancer Care Issues

June 2016, Vol 7, No 5

Combination Immunotherapy the New Standard for Patients with Metastatic Melanoma

Walter Alexander


The key arguments supporting the use of combination therapy with checkpoint blockade immunotherapies as the standard of care for treating metastatic melanoma arise from the combination’s high disease control rates; rapid deep responses; improved response rates; longer progression-free survival (PFS); and good estimated overall survival (OS), approaching 70% at 3 years, said Steven J. O’Day, MD, Professor of Medical Oncology, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, at the recent HemOnc Today Melanoma and Cutaneous Malignancies meeting. [ Read More ]

FDA News – June 2016

FDA Approvals, News & Updates

  • Fluciclovine F18 Diagnostic Imaging Agent Approved to Detect Recurrent Prostate Cancer
  • Tecentriq for Metastatic Urothelial Bladder Cancer
  • Afatinib Receives New Indication for Advanced Squamous-Cell NSCLC
  • FDA Approves Netspot Diagnostic Test to Detect Neuroendocrine Tumors
[ Read More ]

In the Literature – June 2016

In the Literature

  • Afatinib Superior to Gefitinib as First-Line Treatment for EGFR Mutation–Positive NSCLC
  • Combination Chemotherapy plus Radiation Prolongs Survival in Low-Grade Glioma
  • Less Frequent Lung Cancer Screening Warranted in Individuals with Negative Initial Screening
[ Read More ]

Minor Changes in Systemic Therapy Recommendations in NCCN Breast Cancer Guideline

Wayne Kuznar

Breast Cancer

The most recent update of the National Comprehensive Cancer Network (NCCN) guideline on breast cancer has undergone a number of “tweaks” with few major changes. The revisions include new recommendations for preoperative endocrine therapy, optimization of adjuvant endocrine therapy in premenopausal and postmenopausal women, an update on HER2-directed therapy for patients with operable breast cancer, and guidance on new agents for endocrine therapy in metastatic disease. [ Read More ]

Real-World Data Show 2-Year Survival Predicts Long-Term Survival for Metastatic Germ-Cell Testicular Cancer

Phoebe Starr

Genitourinary Cancers

Contemporary treatment has led to improvements in survival for all patients with metastatic testicular germ-cell tumors (GCTs), including poor-risk patients, although they still have worse survival. A new study shows that if poor-risk patients receive curative therapy and survive for at least 2 years, their survival approaches that of favorable-risk and intermediate-risk patients. The study supports no further routine scanning 2 years after diagnosis in surviving patients. [ Read More ]

Telehealth Applications in Patient Care

Rita M. Marcoux, RPh, MBA; F. Randy Vogenberg, PhD, RPh, FASHP

Employers’ Perspective

The term telehealth is used interchangeably with telemedicine by some organizations. However, telemedicine is typically associated with the delivery of traditional clinical diagnosis and monitoring by using some form of medical technology, whereas telehealth has a much broader definition that comprises education, disease awareness, and wellness, in addition to the use of technology to connect physicians to patients. [ Read More ]